University of Michigan, 1992, B.Sc (Chemistry)
University of Michigan, 1995, M. Sc (Biological Chemistry)
University of Michigan, 2001, PhD (Biological Chemistry)
University of Michigan, 2001, MD
Memorial Sloan-Kettering Cancer Center, 2006, Residency (Radiation Oncology)
The overall objective of Dr. Rengan’s research centers on approaches to improve the therapeutic ratio in solid tumors to ionizing photon or proton radiation. His active area of current research is in pre-clinical and clinical strategies to utilize radiation to trigger an anti-tumor immune response in patients with advanced malignancies. He also has an interest in healthcare disparities and expanded access to radiation treatment in low-resource environments. In summary, his research spans across the domains of:
Dr. Rengan’s clinical expertise is in the treatment of thoracic malignancies, including NSCLC, small cell lung cancer, thymoma, and mesothelioma as well as melanoma and renal cell carcinoma. Additionally, he has clinical expertise in the use of proton and particle beam therapy in the management of solid tumors.
4. Functional Imaging-based Dose Escalation in Locally Advanced NSCLC CC 9599